KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$12.09 USD
+0.03 (0.25%)
Updated May 9, 2024 04:00 PM ET
After-Market: $12.09 0.00 (0.00%) 4:30 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KALV 12.09 +0.03(0.25%)
Will KALV be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KALV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KALV
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
KALV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is it a Good Idea to Invest in KalVista (KALV) Stock Now?
Here's Why You Should Invest in Alpine (ALPN) Stock Now
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
Other News for KALV
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)
KalVista price target lowered by $4 at H.C. Wainwright, here's why
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals: A Strong Buy on Strategic Growth and Promising Sebetralstat Prospects
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year